Targeted proteomics techniques differ mainly in what the mass spectrometer is required to know before acquisition and what ion evidence it records during the run. In practice, researchers usually compare multiple reaction monitoring or selected reaction monitoring (MRM/SRM), parallel reaction monitoring (PRM), and data-independent acquisition routes such as DIA or SWATH. MRM/SRM and PRM are closed-list targeted methods. DIA and SWATH are scheduled-window discovery methods that are often discussed beside targeted assays because projects commonly move from open DIA matrices to MRM or PRM confirmation.

Researchers selecting a closed-panel or discovery-to-confirmation path can review the MtoZ Biolabs Targeted Proteomics Service for method-family feasibility before assay development begins.

MRM and SRM: Transition-Locked Targeting

Selected reaction monitoring (SRM) isolates one peptide precursor, fragments it, and detects one predefined product ion. Because both precursor and product are filtered, the method is selective against much of the chemical background on a triple-quadrupole instrument. Multiple reaction monitoring (MRM) is the practical multiplex form of the same idea: several precursor-to-product transitions are scheduled in one method. In proteomics literature, SRM and MRM are often used as overlapping terms for transition-based targeted acquisition.

MRM/SRM therefore requires both the peptide precursor and the quantitative fragment ions to be chosen before the cohort is run. That design supports efficient monitoring of mature panels and can recover low-abundance targets that would be missed if acquisition depended only on the most intense survey-scan peaks. The trade-off is method-development effort: transitions must be optimized and reviewed for interference in the project matrix.

PRM: Precursor Scheduling With Full Product-Ion Spectra

PRM is closely related to MRM/SRM but records a different ion set. PRM isolates scheduled precursors and stores a full high-resolution product-ion spectrum for each target, usually on quadrupole-Orbitrap or quadrupole-time-of-flight platforms. Quantitative and qualifier fragments can be selected or replaced after acquisition. Unlike MRM, PRM does not require every product transition to be locked before the run.

That difference makes early method refinement easier when accurate-mass fragment review is needed in complex digests. It does not make PRM open discovery. Only precursors placed on the inclusion list are measured, and panel size remains limited by chromatographic peak width and MS2 cycle time. Side-by-side selection criteria are discussed in PRM vs MRM: Comparative Analysis in Quantitative Proteomics.

MRM locks transitions before acquisition; PRM locks precursors and reviews fragments afterward; neither surveys an open proteome.

DIA and SWATH: Windowed Discovery Beside Targeted Methods

MRM and PRM need named peptides before acquisition. When the inventory is still open, data-independent acquisition (DIA) is the more relevant discovery route. SWATH is a representative sequential-window DIA implementation: the precursor range is divided into windows, each window is fragmented on a schedule, and peptide quantities are later extracted from fragment chromatograms, often with a spectral library or a library-free model.

DIA therefore differs from classic targeted proteomics in scope. It systematically records fragment evidence across scheduled windows rather than monitoring only an inclusion list. Compared with data-dependent acquisition (DDA), DIA often improves measurement consistency across independent injections for comparative cohorts, but it does not automatically deliver higher accuracy for every peptide, and it does not replace MRM or PRM when a closed confirmation panel is required.

Figure 1. MRM/SRM and PRM quantify closed peptide lists; DIA/SWATH supports open or semi-open inventories through scheduled windows.

Practical Differences That Drive Method Choice

Dimension	MRM / SRM	PRM	DIA / SWATH
List status	Closed transitions	Closed precursors	Open or semi-open inventory
Typical platform	Triple quadrupole	High-resolution MS	High-resolution MS with windowed MS/MS
What is preselected	Precursor and product ions	Precursor and retention window	Window schedule across m/z range
What is recorded	Selected transitions	Full product-ion spectrum	Fragment chromatograms from windows
Main strength	Efficient multiplex on mature panels	Post-acquisition fragment review	Broader relative discovery coverage
Main limit	Transition development and interference	Cycle-time limited panel size	Not a substitute for closed-list confirmation
Default claim	Relative; absolute with SIS	Relative; absolute with SIS	Relative discovery matrix

Mechanism detail for PRM precursor isolation and parallel product-ion readout is covered in Mechanism of Parallel Reaction Monitoring.

Figure 2. Choose DIA while the inventory is open; choose PRM when fragment review is needed on a closed list, or MRM/SRM when transitions are already mature.

When Each Technique Fits

Use MRM or SRM when the peptide panel is closed, transitions are stable, and triple-quadrupole multiplex efficiency is the priority. Use PRM when the panel is closed but matrix interference or early fragment refinement favors high-resolution MS2 review. Use DIA or SWATH when proteins still need to be discovered or ranked before a targeted shortlist is justified. Absolute concentration remains a separate design layer: any of these routes needs stable isotope-labeled standards and calibration when amount units are required.

Diagnostic cutoffs and companion-diagnostic claims sit outside ordinary research MRM, PRM, or DIA reporting unless a separately validated assay framework is declared.

Conclusion

The differences among targeted proteomics techniques are easiest to use when list status and recorded ions are kept distinct. MRM/SRM monitors predefined transitions on triple-quadrupole platforms. PRM schedules precursors and stores high-resolution product-ion spectra for post-acquisition fragment quantification. DIA and SWATH provide scheduled-window discovery rather than closed-list targeting, and they often feed later MRM or PRM confirmation. Matching the method to whether peptides are already named, whether fragment review is required, and whether the claim is relative discovery or calibrated amount prevents both under-scoped panels and overclaimed hybrid methods. Researchers comparing these options can contact MtoZ Biolabs to review target status, matrix type, and reporting needs, and can also consult the MtoZ Biolabs Targeted Proteomics Service for project-specific feasibility and workflow planning.